Head-to-head · Cost-Efficiency Index
Curex vs REMEVi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Curex
People who want a low-cost first month, an oral option, and a verified pharmacy nationwide, and don't need a dose-by-dose price table before signing up.
Visit CurexREMEVi
Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Visit REMEViThe verdict
Curex takes it, leading the Cost-Efficiency Index 81 to 80. A discounted first month ($49-$149) steps up to a 'starting at $199' ongoing rate — real, but not the flat, fully-disclosed price the headline implies, and California loses the injectable route entirely. REMEVi still earns a B− — Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Curex.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Curex | REMEVi |
|---|---|---|
| Cost-Efficiency Index | 81/100 | 80/100 |
| Semaglutide / mo | $199/mo Starting (first month $49) | $219/mo |
| Tirzepatide / mo | $199/mo Starting (first month $149) | $319/mo |
| Semaglutide / yr (modeled) | $2,388 | $2,628 |
| Tirzepatide / yr (modeled) | $2,388 | $3,828 |
| Coverage | All 50 states (California: oral tablet only, no injectable) | All 50 states |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #29 | #33 |
Curex
81/100Where the value is
- Discounted first month well below the ongoing rate — $49 for semaglutide, $149 for tirzepatide
- Nationwide enrollment (all 50 states) plus an oral/sublingual route as an alternative to injections
- 365-day money-back guarantee and a full refund if never prescribed
The tradeoffs
- The '$199/mo' figure is labeled 'Starting,' not flat — no dose-by-dose price table is published, so the real cost at a higher maintenance dose is unverified
- California residents cannot get the injectable route at all — oral tablets only, despite the 'all 50 states' enrollment claim
Regulatory note: the FDA issued a warning letter to Curex in September 2025. We still list and link to Curex; you should know the letter is on the public record before you decide.
REMEVi
80/100Where the value is
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
The tradeoffs
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.